ProCE Banner Activity

ExpressPoints: HER2-Positive Breast Cancer: A Guide Through an Evolving Treatment Landscape

Slideset

Download this short summary slideset on current optimal treatment for patients with HER2-positive breast cancer.

Released: February 09, 2021

Expiration: February 08, 2022

Share

Faculty

Jame Abraham

Jame Abraham, MD, FACP

Enterprise Chair and Professor of Medicine
Department of Hematology and Medical Oncology
Cleveland Clinic
Cleveland, Ohio

Hope S. Rugo

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Puma Biotechnology, Inc.

Faculty Disclosure

Primary Author

Jame Abraham, MD, FACP

Enterprise Chair and Professor of Medicine
Department of Hematology and Medical Oncology
Cleveland Clinic
Cleveland, Ohio

Jame Abraham, MD, FACP, has no relevant financial relationships to disclose.

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, ARC Therapeutics, Artios, Arvinas, AstraZeneca, Bayer, BeyondSpring, BioNTech, Blueprint Medicines, Bristol Myers Squibb/Systimmune, Circle Pharma, Cullinan, CytomX, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui, Incyte, Jazz, Johnson & Johnson/AMBRX, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Natera, Novartis, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Sumitovant, Tango, Umoja Biopharma, Zentalis, Zuellig, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb/Systimmune, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Menarini/Stemline, Merck, Nanostring, Novartis, OncoPep, Pfizer, Sanofi, Seattle Genetics.